Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Poster Presentations

GH & IGFs P3

hrp0089p3-p192 | GH & IGFs P3 | ESPE2018

Good Growth Response to Growth Hormone Therapy in Short Children with Normal Growth Hormone Secretion

Awwa AhmedEl , Soliman Ashraf

The availability of biosynthetic growth hormone (GH) ensures that children who are deficient can have replacement therapy, but it also has created the opportunity to treat children who are short but do not have a deficiency. Non-GH deficient short stature, without treatment, the height outcomes in most studies have failed to reach mid-parental target height. GH therapy resulted in mixed height outcomes; some reached genetic target height whereas others failed. The aim of this ...

hrp0089p3-p193 | GH & IGFs P3 | ESPE2018

Growth Hormone Deficiency Intwo Children with Williams-Beuren Syndrome: The Long-Term Response to Growth Hormone (GH) Therapy

Soliman Ashraf , Adel Ashraf , Alyafiei fawzia

Background: Pre- and postnatal growth retardation of unknown pathogenesis is a common clinical feature in patients with Williams-Beuren syndrome (WBS). However, growth hormone deficiency (GHD) has not been considered a major cause of growth retardation.Case reports: We report two female patients with confirmed WBS who had defective GH secretion in response to two provocative tests and low IGF-I level and their growth response to GH therapy for 9 years. T...

hrp0089p3-p194 | GH & IGFs P3 | ESPE2018

Growth Hormone Treatment: Does Timing Matter?

Marques Bernardo , Gomes Sonia Madeira , Caetano Joana Serra , Cardoso Rita , Dinis Isabel , Mirante Alice , Fitas Ana Laura , Diamantino Catarina , Limbert Catarina , Pina Rosa , Lopes Lurdes

Introduction: Treatment with recombinant growth hormone (rGH) is safe and has greatly improved the approach of children and adolescents with growth hormone deficiency (GHD) and other growth disorders. Some studies show that most of the height gain associated with GH treatment occurs in prepubertal years. The aim of our study was to evaluate the effect of age at start of the treatment on final height in children with isolated or GHD in a Portuguese cohort.<p class="abstext"...

hrp0089p3-p195 | GH &amp; IGFs P3 | ESPE2018

Support for Patients Treated with Growth Hormone to Reach their Growth Potential: Addressing Adherence Barriers through Personalised Behavioural Patient-support Programmes

Moloney Clare , Malik Sumaira , Cancela Jorge , Koledova Ekaterina

Background: Recombinant human growth hormone (r-hGH) treatment can optimise growth potential; however, optimum outcomes are not always achieved owing to several reasons, including poor adherence. This analysis sought to operationalize psychosocial drivers of non-adherence in GH patients, using the three-component, evidence-based capability, opportunity and motivation behavioural framework (COM-b). The framework allows for matching of specific interventions to help modify behav...

hrp0089p3-p196 | GH &amp; IGFs P3 | ESPE2018

Main Discrepancies between Predicted and Observed Growth Responses with iGRO in Children Treated with GHr in Spain

Palma Cristina Mora , Martin Nerea Itza , Fernandez Julio Guerrero , Fresno Luis Salamanca , Bonis Ana Coral Barreda , Casado Isabel Gonzalez

Introduction: Growth prediction algorithms (i.e. iGRO), provide an estimate of a patients’ likely growth in the first year, and subsequent years, of GH treatment at a given dose, taking into account the patient’s combination of physical characteristics. Comparing a patient’s actual growth with their predicted growth after the first year of GH treatment, it is possible to determine whether the patient is responding to GH as expected (Index of responsiveness; IoR)...

hrp0089p3-p197 | GH &amp; IGFs P3 | ESPE2018

Adherence and Long-term Outcomes of Therapy in Pediatric Subjects in Greece Using Easypod™ Electromechanical Device for Growth Hormone Treatment: The Phase IV Multicentre Easypod™ Connect Observational Study (ECOS)

Charmandari Evangelia , Michalakos Stefanos , Sakellariou Dimitris , Koledova Ekaterina , Chrousos George

The Easypod™ Connect Observational Study (ECOS) was the first global study of easypod™, currently the only electronic injection device for recombinant human growth hormone (r-hGH; Saizen®). ECOS reported accurate and robust real-time adherence data in a large cohort of patients. In this analysis, we assess the adherence of r-hGH administered via easypod™ in a cohort of Greek patients from ECOS (EMR200104-520, NCT01363674). Patients aged 2–18...

hrp0089p3-p198 | GH &amp; IGFs P3 | ESPE2018

Growth Hormone Deficiency in Neurofibromatosis: Report of Four Cases

Guidoni Elisa , Lotti Federica , Geronzi Ursula , Sorrentino Laura Arianna , Grosso Salvatore , Municchi Giovanna

Introduction: Short stature is frequently associated to neurofibromatosis (NF). In these patients this condition is often caused by growth hormone (GH) deficiency. We describe four boys affected by NF type 1 and GH deficiency treated with GH replacement therapy.Case report: GH deficiency was diagnosed in four patients with NF type 1, who were referred to our Pediatric Endocrinology Unit for short stature. Patient 1 started GH replacement therapy at the C...

hrp0089p3-p199 | GH &amp; IGFs P3 | ESPE2018

Extremely Low Body Mass Index Negatively Impact the Response to Growth Hormone Treatment in Children with Growth Hormone Deficiency

Nicolaescu Irina Delia , Dinca Denisa , Albu Alice

Introduction: The nutritional status of a child is essential for the overall development and in particular for the statural growth. It was previously reported that growth hormone (GH) administration in children with growth hormone deficiency (GHD) could have a beneficial effect on body mass index (BMI) in both underweight and overweight children, suggesting a complex interplay between nutrition and growth. Therefore, the aim of the study was to analyze the influence of BMI on ...

hrp0089p3-p200 | GH &amp; IGFs P3 | ESPE2018

Small for Gestational Age (SGA) Patients with Premature Treatment Discontinuation: Their Journey in French Real-life Settings

Salles Jean-Pierre , Coutant Regis , Leheup Bruno , Nicolino Marc , Hacques Evguenia , Villette Beatrice

Objective: Premature GH treatment discontinuation of SGA is usually linked to safety or ineffectiveness. However, this population is poorly addressed compared to those with final adult height (FAH). Authors investigated the journey of SGA prematurely discontinued Norditropin® treatment in a French real-life.Methods: Observational prospective ongoing study: 291 Norditropin®-treated SGA. Annual FU up to FAH. Descriptive anal...

hrp0089p3-p201 | GH &amp; IGFs P3 | ESPE2018

Effects on Near-adult Height and Safety of Recombinant Human Growth Hormone in Growth Hormone Deficiency and Turner Syndrome Patients: Results from the LG Growth Study

Choi Jin-Ho , Chung Sochung , Rhee Young-Jun , Hyun Kim Jae , Chae Hyun-Wook , Yoo Jae-ho , Lee Young Ah , Hwang Il Tae

Objectives: This study was performed to evaluate effectiveness on near-adult height (NAH) and safety of recombinant human growth hormone (rhGH) (Eutropin® Inj., Eutropin®Plus Inj., Eutropin®AQ Inj., LG Chem, Ltd.) treatment in children with growth hormone deficiency (GHD) and Turner syndrome (TS).Methods: The LG Growth Study (LGS) is a multicenter, long-term, observational study designed to evaluate the lon...

hrp0089p3-p202 | GH &amp; IGFs P3 | ESPE2018

Final Adult Height After Growth Hormone Treatment in Patients with Turner Syndrome

Ahn Jungmin , Suh Junghwan , Kim Hoseong , Kwon Ahreum

This study aimed to evaluate final adult height after recombinant growth hormone (GH) treatment in girls with Turner syndrome (TS) and elucidate the contributing factors to growth response. (Seventy-four patients with Turner syndrome who were treated with GH and reached adult height and 18 patients without treatment were enrolled in this study. To determine final height gain, we assessed the difference between the final height standard deviation score (SDS) and height SDS at t...

hrp0089p3-p203 | GH &amp; IGFs P3 | ESPE2018

Results of Mecasermin Treatment in Pediatric Patients Evaluated for Severe and Partial Primary Deficiency of IGF-1

Stozek Karolina , Bossowski Artur

Background: Severe primary deficiency of insulin-like growth factor-1 (IGFD) being characterized by growth failure and short stature in children, constitutes an indication to recombinant human IGF-1 (mecasermin) treatment. It is defined by serum insulin-like-growth factor-1 (IGF-1) levels less than or equal to 2.5 th percentile, height less than or equal to −3 S.D.S., normal growth hormone (GH) secretion and exlusion of secondary causes of IGFD.<p clas...

hrp0089p3-p204 | GH &amp; IGFs P3 | ESPE2018

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

Vazquez Veronica Maria Padin , Costa David Albino Gomez , Garcia Aida Del Campo , Cordo Lourdes Rey , Martin Jose Luis Chamorro , Lorenzo Jose Ramon Fernandez

Introduction: Short stature is defined as stature less than −2 standars deviations (SD) for a person’s age and sex of the reference population. Short for gestational age children (SGA) represent 20% of all children with short stature. 10% of these can not catch-up and remains their height below −2 SD. Growth hormone (GH) treatment is a recognized therapy for SGA children authorized in Europe at 4 years old. There are studies that support that younger children ...

hrp0089p3-p205 | GH &amp; IGFs P3 | ESPE2018

Small for Gestational Age (SGA) Patients in Real Life French Clinical Practice: What is the Difference Between Good and Poor Responders to GH Treatment

Nicolino Marc , Coutant Regis , Leheup Bruno , Salles Jean-Pierre , Hacques Evguenia , Villette Beatice

Objective: Age and height at treatment start, target height, GH dose, and first year treatment response are among known criteria of GH deficiency (GHD) good responders (final adult height [FAH] >−2 standard deviation score [S.D.S.]) to GH treatment (GHT). The authors investigated whether the same criteria are applicable to SGA patients based on real-life ongoing French registry data.Methods: 291 SGA children treated with Norditro...

hrp0089p3-p206 | GH &amp; IGFs P3 | ESPE2018

Body Mass Index (BMI) in Patients with Growth Hormone Deficiency (GHD) at Diagnosis, One Year and Two Years After Treatment with Growth Hormone (GH)

Schmitt-Lobe Maria Claudia , Costa Debora Regina Andrade Dalla , Ueno Rafael Koji Yoshimatsu

Introduction: Growth velocity is reduced in patients with GH deficiency and this may result in an increase in Body Mass Index (BMI). Treatment performed with Growth Hormone (GH) while accelerating growth velocity, might reduce BMI. The objective of this study was to evaluate BMI in patients with GHD at diagnosis, 1 y and 2 y after started treatment with GH and to compare if there is difference between the BMI of the patients with and without pituitary abnormalities.<p clas...

hrp0089p3-p207 | GH &amp; IGFs P3 | ESPE2018

Erythropoietin and Granulocyte Macrophage Colony Stimulating Factor Levels in Growth Hormone Deficient Children after 1 Year of Growth Hormone Therapy

Pankratova Maria , Vorontsova Maria , Yusipovich Alexander , Shiryaeva Tatiana , Peterkova Valentina

Background/Aims: An increase in growth rate in children suffering from growth hormone deficiency (GHD) subjected to recombinant growth hormone treatment (rGHT) was shown to be accompanied by acceleration of metabolic processes that may stimulate hematopoiesis. Therefore, the aim of the present study was to examine the effects of one year rGHT on erythropoietin (EPO) and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) levels in GHD children.Meth...

hrp0089p3-p208 | GH &amp; IGFs P3 | ESPE2018

Cost-effectiveness of Growth Hormone Therapy in Children in Russia

Vorontsova Maria , Nagaeva Elena , Naigovzina Nelli

Background: Growth hormone deficiency (GHD) in children is a rare condition, which requires pathogenic therapy. In Russia GH treatment (GHT) is part of a federal program called “Seven high expenditure diseases” (7HED) and is fully state funded. In the rare cases when a GHD child cannot be treated with GH, financial and medical support for the child and its family is provided by the state. It is therefore important to understand the cost-effectiveness of GHT for child...

hrp0089p3-p209 | GH &amp; IGFs P3 | ESPE2018

Vitamin D Status in Children with Isolated Idiopathic GH Deficiency (GHD) in North and Central Greece

Tsiroukidou Kyriaki , Xatzipsalti Maria , Mameka Iliana , Polychroni Ioulia , Vamvakis Anastasios , Papagianni Maria , Stamogiannou Lela

Background: Vitamin D status in children with isolated GHD has been analyzed in few studies with controversial results. The aim of the study was to assess vitamin D status in children with idiopathic GHD in North and Central Greece.Materials and methods: 128 children (M/F: 76/61, mean age 9.5 (S.D.±3.5 years) with isolated GHD were compared with 65 controls (M/F: 46/3, mean age 9.3 (S.D.±3.2 years). Children were d...

hrp0089p3-p210 | GH &amp; IGFs P3 | ESPE2018

A Pilot Study for Comparing Efficacy and Safety of the CinnaTropin® to the Reference Recombinant Human GH in Children with Isolated GH Deficiency and Multiple Pituitary Hormone Deficiency

Razzaghy-Azar Maryam , Pourmotabbed Abdoreza , Heshmat Ramin , Rezaei Farhang

Background: CinnaTropin® (CinnaGen, Iran) is a recombinant human GH manufactured in Iran. Herein, we compared the efficacy and safety of the CinnaTropin® with the corresponding reference (Nordilet® Norditropin, Novo Nordisk, Denmark) in children with idiopathic GH deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD).Methods: This was a randomized, open-label and cross-over study. Eligible pati...

hrp0089p3-p211 | GH &amp; IGFs P3 | ESPE2018

Study of the Effectiveness of GH in Children Born Small for Gestational Age in an Area of Northwestern Spain and its Associated Factors

Rodriguez Paloma Cabanas , Cordo Lourdes Rey , Fernandez Antonio Bello , Martin Jose Luis Chamorro , Carro Ana Prado , Rego Ruben , Castro-Feijoo Lidia , Dans Alicia Cepedano , Conde Jesus Barreiro

Introduction: Recombinant GH is an effective treatment for short children who are born small for gestational age(SGA). Short children SGA who fail catch-up growth by 4 years of age are candidates for GH treatment, at a dose of 35–70 μg/kg per day. Factors associated with response to GH treatment during the initial 2–3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. It is important to kno...

hrp0089p3-p212 | GH &amp; IGFs P3 | ESPE2018

Height Velocity and Height Gain in the First Year of GH Treatment: Predictive Factors of Good Statural Response in Small for Gestational Age (SGA) Patients

Coutant Regis , Leheup Bruno , Nicolino Marc , Salles Jean-Pierre , Hacques Evguenia , Villette Beatrice

Objective: Bang et al. showed that Δ height and growth velocity (GV) the first year of treatment could be predictive factors of statural response in SGA (n=54). Poor responders showed GV <1SDS (55%) and Δ height <0.5SDS (45%). Moreover, Ortego et al. seems to confirm the suitability interest of KIGS mathematical model in a retrospective SGA cohort (n=103) showing that the percentage of good responders in the first year varies betwee...

hrp0089p3-p213 | GH &amp; IGFs P3 | ESPE2018

Role of Insulin like Growth Factors on the Growth Parameters in Children with Acquired Hypothyroidism: An Analysis

Yadav Sangita , Goel Ruchi , Mantan Mukta , Mishra T K

Introduction: Growth retardation as clinical manifestation among children with acquired hypothyroidism is observed later in the course of the illness. Thyroid hormones along with insulin like growth factors (IGF) have important role in somatic and skeletal growth. Studies addressing role of IGF’s towards growth retardation in children with acquired hypothyroidism are limited.Objective: To evaluate effect of Insulin like growth factors in children wi...

hrp0089p3-p214 | GH &amp; IGFs P3 | ESPE2018

Two Siblings with Short Stature

V Sri Nagesh , Dauber Andrew , Kanithi Ravishankar , Dutta Deep , G Ram Kumar

2 siblings were referred for evaluation fo short stature and failure to thrive. Both were born of 3rd degree consanguinity, first and second in birth order. the first sibling was 2 1/2 year old at time of referral and had birthweight of 3.1 kg and had gross motor delay. Present height was 65 cm (SDS −6.2 S.D.)and weight was 6 kg (<3rd centile) Second sibling was 1.5 years old, with gross motor delay with height of 57 cm (SDS −6.5 S.D.</sma...

hrp0089p3-p215 | GH &amp; IGFs P3 | ESPE2018

RHGH Replacement Therapy and Side-Effects: A Retrospective Study of 10 Years

Parastatidou Stavroula , Lampropoulou Dionysia , Zosi Paraskevi , Georga Soultana , Eufraimidou Elissavet , Vlachou Thomais

Treatment with Recombinant Human GH (rhGH) has been of significant value in promoting quality of life in children with GH deficiency. However, it has been associated with several side-effects in the literature, including hypothyroidism, usually transient during the replacement therapy. The aim of this study was to evaluate the side effects of hGH replacement therapy, among children who were followed up at the Pediatric Endocrinology Outpatients Unit of our hospital during the ...

hrp0089p3-p216 | GH &amp; IGFs P3 | ESPE2018

Efficacy and Safety of Recombinant Human GH in Treating Chinese Children with Idiopathic Short Stature

Ying Yanqin , Hou Ling , Yan Liang , Wu Wei , Luo Xiaoping

This study aims to investigate the efficacy and safety of recombinant human GH (rhGH) in the treatment of idiopathic short stature (ISS).Methods: The data of 200 ISS children, who were treated with rhGH from January 2008 to December 2016, were collected and retrospectively analyzed. The data of height, bone age, blood glucose, insulin, thyroid function and IGF-1 were collected, and annual growth rate (AGR), height standard deviation score (HtSDS) and rel...

hrp0089p3-p217 | GH &amp; IGFs P3 | ESPE2018

Comparison the Recombinant Human GH (rhGH) Treatment in Children with Idiopathic Short Stature (ISS) and GH Deficiency (GHD)

Ying Yanqin , Hou Ling , Liang Yan , Wu Wei , Luo Xiaoping

Background: The efficacy and safety of rhGH treatment on ISS and GHD were not reported in Chinese children. In this study, we aimed to compare the efficacy and safety of rhGH therapy in ISS and GHD.Methods: The clinical data in children with ISS and GHD who were treated with rhGH for more than one year from 2005 to 2016 were retrospectively analyzed. Growth velocity (GV), HtSDS, IGF1 SDS, BMI and the incidence of fasting hyperglycemia, fasting hyperinsul...

hrp0089p3-p218 | GH &amp; IGFs P3 | ESPE2018

Bone Age Maturation During the Three Years of GH Treatment in Patients with Idiopathic GH Deficiency and Idiopathic Short Stature: Analysis of Data from LG Growth Study

Shim Young Suk , Hwang Il Tae , Yang Seung , Kim Eun Young

Background: Although the beneficial effects of GH treatment on statural growth are well known, the impacts on skeletal maturation are not fully understood. In the current study, we aimed to investigate the progression of bone age (BA) in children with idiopathic GH deficiency (iGHD) and idiopathic short stature (ISS) based on a LG Growth Study (LGS). We also evaluated the progression rate of BA relative to chronologic age (CA) between iGHD and ISS and to find their associated ...

hrp0089p3-p398 | GH &amp; IGFs P3 | ESPE2018

Recombinant Growth Hormone Therapy in Prepubertal Children with Idiopathic Short Stature in Korea: A Phase III Randomized Trial

Im Minji , Kim J , Suh B-K , Ko CW , Lee K-H , Shin CH , Hwang JS , Kim HS , Chung WY , Kim CJ , Han H-S , Kwon NY , Cho SY , Yoo H-W , Jin D-K

Several studies have evaluated the effects of growth hormone (GH) on auxological and biochemical parameters in children with non-GH-deficient, idiopathic short stature (ISS). This study evaluated the efficacy and safety of GrowtropinR-II (recombinant human GH) in Korean patients with ISS. This was a 1-year, open-label, multicenter, phase III randomized trial of Growtropin-II in Korean patients with ISS. In total, 70 prepubertal subjects (39 males, 31 females) betwee...